Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: minemura h. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H, Sugiyama T, Tamura T, Minemura H, Kaira K, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: minemura h. Cancer Chemother Pharmacol. 2017 Sep;80(3):615-622. doi: 10.1007/s00280-017-3403-9. Epub 2017 Jul 31. Cancer Chemother Pharmacol. 2017. PMID: 28761968 Free PMC article.
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: minemura h. Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8. Cancer Chemother Pharmacol. 2018. PMID: 29737372
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
Imai H, Yamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: minemura h. Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14. Chemotherapy. 2018. PMID: 30107372
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H, Yamada Y, Minemura H, Sugiyama T, Kotake M, Kaira K, Kanazawa K, Nakamura Y, Kasai T, Shibata Y, Kaburagi T, Minato K; Gunma-Ibaragi-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: minemura h. Thorac Cancer. 2018 Dec;9(12):1699-1706. doi: 10.1111/1759-7714.12884. Epub 2018 Oct 3. Thorac Cancer. 2018. PMID: 30281216 Free PMC article.
Serum decorin is a potential prognostic biomarker in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Nikaido T, Tanino Y, Wang X, Sato Y, Togawa R, Kikuchi M, Misa K, Saito K, Fukuhara N, Kawamata T, Rikimaru M, Umeda T, Morimoto J, Koizumi T, Suzuki Y, Hirai K, Uematsu M, Minemura H, Fukuhara A, Sato S, Saito J, Yokouchi H, Kanazawa K, Shibata Y. Nikaido T, et al. Among authors: minemura h. J Thorac Dis. 2018 Sep;10(9):5346-5358. doi: 10.21037/jtd.2018.08.60. J Thorac Dis. 2018. PMID: 30416782 Free PMC article.
A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report.
Suzuki Y, Kanazawa K, Kanai R, Tomita H, Saito M, Watanabe N, Morimoto J, Umeda T, Kawamata T, Rikimaru M, Koizumi T, Togawa R, Sato Y, Hirai K, Uematsu M, Minemura H, Nikaido T, Fukuhara A, Sato S, Saito J, Tanino Y, Mori K, Shibata Y. Suzuki Y, et al. Among authors: minemura h. Lung Cancer. 2019 Oct;136:105-108. doi: 10.1016/j.lungcan.2019.08.018. Epub 2019 Aug 20. Lung Cancer. 2019. PMID: 31479879
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Imai H, et al. Among authors: minemura h. J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18. J Cancer Res Clin Oncol. 2020. PMID: 31853661
Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, Osaki T, Kasahara N, Uchino J, Sugiyama T, Ishihara S, Ishii H, Naruse I, Mori K, Kotake M, Kanazawa K, Minato K, Kagamu H, Kaira K. Yamaguchi O, et al. Among authors: minemura h. Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771. doi: 10.1007/s00280-020-04055-7. Epub 2020 Mar 19. Cancer Chemother Pharmacol. 2020. PMID: 32193618
82 results